Welcome!

News Feed Item

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatty Liver Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Fatty Liver Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Fatty Liver Disease 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Fatty Liver Disease Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Fatty Liver Disease 33
Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 33
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Merck & Co., Inc. 35
Clinical Trial Overview of Merck & Co., Inc. 35
Galmed International Ltd. 36
Clinical Trial Overview of Galmed International Ltd. 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
PharmaKing Co., Ltd. 38
Clinical Trial Overview of PharmaKing Co., Ltd. 38
Abbott Laboratories 39
Clinical Trial Overview of Abbott Laboratories 39
TCM Biotech International Corp 40
Clinical Trial Overview of TCM Biotech International Corp 40
Sanofi 41
Clinical Trial Overview of Sanofi 41
Phenex Pharmaceuticals AG 42
Clinical Trial Overview of Phenex Pharmaceuticals AG 42
GW Pharmaceuticals plc 43
Clinical Trial Overview of GW Pharmaceuticals plc 43
Genextra S.p.a. 44
Clinical Trial Overview of Genextra S.p.a. 44
Clinical Trial Overview of Top Institutes / Government 45
The National Institute of Diabetes and Digestive and Kidney Diseases 45
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 45
Tabriz University of Medical Sciences 46
Clinical Trial Overview of Tabriz University of Medical Sciences 46
Third Military Medical University 47
Clinical Trial Overview of Third Military Medical University 47
University of Michigan 48
Clinical Trial Overview of University of Michigan 48
Tehran University of Medical Sciences 49
Clinical Trial Overview of Tehran University of Medical Sciences 49
Washington University School of Medicine 50
Clinical Trial Overview of Washington University School of Medicine 50
University of California, San Diego 51
Clinical Trial Overview of University of California, San Diego 51
FUDAN University 52
Clinical Trial Overview of FUDAN University 52
Ahvaz Jundishapur University of Medical Sciences 53
Clinical Trial Overview of Ahvaz Jundishapur University of Medical Sciences 53
Bambino Gesu Hospital and Research Institute 54
Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 54
Five Key Clinical Profiles 55
Appendix 82
Abbreviations 82
Definitions 82
Research Methodology 83
Secondary Research 84
About GlobalData 84
Contact Us 84
Disclaimer 84
Source 85

List of Tables
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Fatty Liver Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 35
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International Ltd., 2014* 36
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by PharmaKing Co., Ltd., 2014* 38
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 39
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by TCM Biotech International Corp, 2014* 40
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 41
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Phenex Pharmaceuticals AG, 2014* 42
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by GW Pharmaceuticals plc, 2014* 43
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2014* 44
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014* 45
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tabriz University of Medical Sciences, 2014* 46
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Military Medical University, 2014* 47
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 48
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 49
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 50
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 51
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 52
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ahvaz Jundishapur University of Medical Sciences, 2014* 53
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital and Research Institute, 2014* 54

List of Figures
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 83

Read the full report:
Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
Identity is in everything and customers are looking to their providers to ensure the security of their identities, transactions and data. With the increased reliance on cloud-based services, service providers must build security and trust into their offerings, adding value to customers and improving the user experience. Making identity, security and privacy easy for customers provides a unique advantage over the competition.
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
StarNet Communications Corp has announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 to safely tunnel the remote desktops from Linux and Unix servers to the user’s PC over encrypted SSH. Traditionally, users of PC X servers deploy the XDMCP protocol to display remote desktop environments such as the Gnome and KDE desktops on Linux servers and the CDE environment on Solaris Unix machines. XDMCP is used primarily on comp...